Health Update Update

For indispensable reporting on the coronavirus crisis and more, subscribe to Mother Jones' newsletters.


As you may recall, the key thing my doctor—and I—would like to see on the multiple myeloma front is a big drop in my M protein level, a marker for cancerous plasma cells. Today we got the latest results, and it’s up to 0.9. Since the first round of chemotherapy had already gotten it down to 1.0, what this means is that the entire second round of chemotherapy at City of Hope was basically useless. I didn’t respond to it at all.

We went ahead with the biopsy today anyway, for reasons that are a little vague to me. Apparently it will give us some indication of where the cancerous cells are, but the results won’t have any impact on my treatment plan. In a couple of days I’ll start on a low daily dose of Revlimid, in hopes that it will get my M protein level down to zero. If it doesn’t, then we’ll try a higher dose.

Revlimid is a highly controlled substance because it’s in the same family as thalidomide and can cause serious birth defects. You cannot just pick it up at your local pharmacy. First, you have to fill out a lengthy form, and the medication is then mailed from a central location, presumably in a plain brown wrapper or something. As near as I could tell, pretty much every question on the form was some variation of me promising not to even think about getting anyone pregnant while I’m taking it. As you can imagine, this is not really an issue, so the form turned out not to be too much of a chore after all. It was just OK, OK, OK, OK, etc. I promise.

So that’s it for now. Not exactly cheery news, but the buildup of cancerous cells in my bone marrow is not actually that heavy (about 5 percent or so), which means there’s a decent chance the Revlimid will be enough to keep it under control. We’ll know in a couple of months or so.

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.